Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval

Sevigny J , Chiao P , Bussiere T , et al. The antibody aducanumab reduces abeta plaques in Alzheimer's disease. Nature, 2016; 537:50–56.

Lin GA , Whittington MD , Synnott PG , et al. Aducanumab for Alzheimer's disease: effectiveness and value; draft evidence report. Institute for Clinical and Economic Review. 2021. https://icer.org/assessment/alzheimers-disease-2021/ Accessed July 10, 2021 .

U.S. FDA. Food and Drug Administration , Center for Drug Evaluation and Research . Periphearl and central nervous system drugs advisory committee virtual meeting. 2020. https://www.fda.gov/media/145691/download Accessed June 25, 2021

Knopman DS , Jones DT , Greicius MD . Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement, 2021; 17:696–701.

Biogen Inc. Aduhelm (aducanumab) [package insert]. U.S. Food and Drug Administration website. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf Accessed June 25, 2021 .

Alexander GC , Emerson S , Kesselheim AS . Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA, 2021; 325:1717–1718.

Alexander GC , Karlawish J. The problem of aducanumab for the treatment of alzheimer disease. Ann Intern Med. DOI: 10.7326/M21-2603

2021 Alzheimer's disease facts and figures. Alzheimers Dement 2021;17:327–406.

Kaiser Family Foundation. FAQs on Medicare financing and trust fund solvency. 2021. https://www.kff.org/medicare/issue-brief/faqs-on-medicare-financing-and-trust-fund-solvency/ Accessed June 25, 2021 .